Blood analysis specialist Cellavision has appointed Steve Ferguson as its new CEO, effective immediately. He succeeds Simon Østergaard, who will remain with the company during a transition period.
'The Board believes that now is the right time for new leadership to steer Cellavision toward a sharper commercial focus, creating a stronger growth agenda for the current portfolio and executing the commercialization of the existing innovation pipeline', the company stated in a press release.
Ferguson brings over 25 years of experience in the biotechnology sector, most recently serving as CEO of Medix Biochemica. His previous tenure includes roles at Thermo Fisher Scientific and Lundbeck.
'Steve Ferguson has a strong commercial background. Over the coming years, Cellavision will focus heavily on launching and commercializing its current innovation portfolio, and strong commercial leadership is required to ensure success', said Chairman of the Board Zlatko Rihter in a statement.
Cellavision has underperformed on the stock market in recent years, with the share price declining 35 percent over the last twelve months and more than 60 percent over the past five years.
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
